Clin2
NCT06036004Possibly a fitRecruiting

Oxytocin therapy for anxiety in diabetes insipidus

Central Diabetes Insipidus (cDI)

Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests whether oxytocin, a hormone that helps with social bonding and stress, can improve anxiety or emotional awareness in people with central diabetes insipidus (a condition where the body can't regulate water balance). It may be a good fit if you have high anxiety or trouble identifying your feelings.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
112 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with central diabetes insipidus (a condition where the body loses too much water).
  • You have high anxiety (score of 39 or more on a standard anxiety questionnaire) or difficulty recognizing and describing your feelings (score of 52 or more on a questionnaire).
  • You have been stable on your current hormone replacement therapy (desmopressin) for at least three months.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.
  • You have not taken any experimental drugs in the last 30 days.
  • You do not have a current or past psychotic disorder (like schizophrenia).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07265180Recruiting
Oxytocin and group therapy for schizophrenia

This trial tests whether adding oxytocin (a hormone that helps with social bonding) to group therapy can improve symptoms and social functioning in people with schizophrenia. It compares two different doses of oxytocin to see which works better.

Berlin, State of Berlin
NCT06676774Recruiting· Phase 2
Does oxytocin nasal spray help people with diabetes insipidus?

This study tests if a nasal spray with oxytocin (a natural hormone) can improve emotion recognition and reduce stress-related hormone levels in people with central diabetes insipidus compared to healthy volunteers.

Basel
NCT06789705Recruiting
MDMA for people with vasopressin deficiency

This study tests whether a low dose of MDMA, compared to a placebo, changes oxytocin levels in people with a condition called arginine vasopressin deficiency (also known as central diabetes insipidus). The goal is to understand the role of oxytocin in this condition and explore potential treatment insights.

Basel
NCT06334172Recruiting
Can oxytocin control blood sugar?

This trial tests if the hormone oxytocin helps control blood sugar levels. It may offer insight into new ways to manage glucose. You may be a good fit if you are a healthy adult with a normal BMI.

Hellerup, Capital Region
NCT04789148Recruiting· Phase 1
Nasal oxytocin trial for people with hormone deficiency

This early-phase study tests whether a spray of oxytocin in the nose can be given safely and may affect symptoms in people with arginine-vasopressin deficiency. You might qualify if your hormone levels are stable and you can safely take the nasal study medicine during the study period.

Boston, Massachusetts
NCT06364228Recruiting· Phase 2
Oxytocin nasal spray for dementia caregivers

This study tests whether a daily oxytocin nasal spray can help reduce stress and improve well-being in women who care for a family member with dementia. You would take the spray for 10 days and have brain scans and questionnaires.

Omaha, Nebraska

Hear when a new Central Diabetes Insipidus (cDI) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.